LUPKYNIS Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7332472 | AURINIA | Cyclosporine analogue mixtures and their use as immunomodulating agents |
Oct, 2024
(5 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10286036 | AURINIA | Protocol for treatment of lupus nephritis |
Dec, 2037
(13 years from now) | |
| US11622991 | AURINIA | Protocol for treatment of lupus nephritis |
Dec, 2037
(13 years from now) | |
Lupkynis is owned by Aurinia.
Lupkynis contains Voclosporin.
Lupkynis has a total of 3 drug patents out of which 0 drug patents have expired.
Lupkynis was authorised for market use on 22 January, 2021.
Lupkynis is available in capsule;oral dosage forms.
Lupkynis can be used as treatment of patients with active lupus nephritis.
Drug patent challenges can be filed against Lupkynis from 22 January, 2025.
The generics of Lupkynis are possible to be released after 07 December, 2037.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 22, 2026 |
Drugs and Companies using VOCLOSPORIN ingredient
NCE-1 date: 22 January, 2025
Market Authorisation Date: 22 January, 2021
Treatment: Treatment of patients with active lupus nephritis
Dosage: CAPSULE;ORAL
More Information on Dosage
LUPKYNIS family patents
